Aerie boost­ed as Valean­t's trou­bled Tam­pa fa­cil­i­ty looks like it's com­ing out of re­hab

Just days af­ter Valeant $VRX and its late-stage eye drug la­tanoprostene bun­od were turned away by the FDA for the sec­ond time af­ter its Bausch + Lomb man­u­fac­tur­ing fa­cil­i­ty in Tam­pa failed to mea­sure up to fed­er­al stan­dards, the trou­bled biotech says it’s clear­ly on track to now snag a clean bill of health from in­spec­tors.

And while Valeant still has to re­file, once again, the news buoyed shares of Aerie, which re­lies on the fa­cil­i­ty for its sup­plies of Rho­pres­sa, a glau­co­ma drug now un­der re­view at the FDA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.